Esperion Therapeutics | ESPR - Pre Tax Profit


Esperion Therapeutics reported $63.67M in Pre-Tax Profit for its fiscal quarter ending in December of 2025.





Pre Tax Profit Change Date
AbbVie USD 5.57B 2.9B Mar/2026
Alnylam Pharmaceuticals USD 221.65M 60.52M Mar/2026
Alterity Therapeutics Limited AUD -4.74M 3.53M Dec/2024
Amarin USD -852K 7.26M Dec/2025
Amgen USD 1.51B 2.41B Dec/2025
Biogen USD 377.7M 433.7M Mar/2026
BioMarin Pharmaceutical USD 141.2M 168.36M Mar/2026
Cipla INR 7.49B 4.2B Mar/2026
CSL USD 2.61B 1.21B Dec/2025
Cytokinetics USD -206.03M 23M Mar/2026
Daiichi Sankyo JPY 106.73B 48.96B Dec/2025
Eli Lilly USD 8.27B 1.03B Dec/2025
Esperion Therapeutics USD 63.67M 95M Dec/2025
Geron USD -3.64M 27.5M Mar/2026
Grifols EUR 257.85M 190.87M Dec/2024
Halozyme Therapeutics USD 180.33M 281.18M Mar/2026
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Ionis Pharmaceuticals USD -93M 135M Mar/2026
Merck USD 3.42B 3.32B Dec/2025
Minerva Neurosciences USD 22.51M 30.74M Sep/2024
Moderna USD -799M 612M Dec/2025
Nektar Therapeutics USD -34.7M 2.35M Dec/2025
Pfizer USD 5.18B 6.82B Mar/2026
PTC Therapeutics USD -2.46M 136.62M Mar/2026
Puma Biotechnology USD 20.61M 24.76M Sep/2024
Regeneron Pharmaceuticals USD 1.04B 719.6M Dec/2025
Sanofi EUR -1.16B 5.5B Dec/2025
Sarepta Therapeutics USD 343.17M 750.85M Mar/2026
United Therapeutics USD 444M 6M Dec/2025
Vanda Pharmaceuticals USD -22.92M 16.68M Dec/2024